Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisaborole versus vehicle and active topical controls in mild to moderate atopic dermatitis
2018-001043-31Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of crisaborole in atopic dermatitis (AD) (4 arms), sponsored by Pfizer. Primary endpoint: Percent change from baseline in Eczema Area and Severity Index total score at Day 29. Started Sep 2018; status: terminated.
02
Drugs
crisaborole
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001043-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001043-31.